tag:blogger.com,1999:blog-36634196.post3125519042181355660..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: ADA Wrap-Up: Where's The Chocolate?Chris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-36634196.post-81539465402905558772008-06-13T07:35:00.000-05:002008-06-13T07:35:00.000-05:00Thanks Chrisindeed Rheo is having a head to head s...Thanks Chris<BR/>indeed Rheo is having a head to head study with Actos, i just checked up the website.<BR/>I do agree its a tough task, would have to wait and watch.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-86701903257110741492008-06-12T10:09:00.000-05:002008-06-12T10:09:00.000-05:00maybe the PPAR class isn't dead but it'll require ...maybe the PPAR class isn't dead but it'll require quite a bit of work to resuscitate at least as far as getting new drugs on the market is concerned. <BR/><BR/>we've written about the Rheoscience candidate--partnered with Dr. Reddy's--on the blog before. See http://invivoblog.blogspot.com/2007/08/is-partial-agonism-key-to-ppar-success.html <BR/><BR/>seemed to me at the time of writing that post that if a drug's going to make it past FDA comparison studies to Actos might be necessary, and that's what Rheo's doing.Chris Morrisonhttps://www.blogger.com/profile/04075266444951558159noreply@blogger.comtag:blogger.com,1999:blog-36634196.post-48703726934005607762008-06-12T07:48:00.000-05:002008-06-12T07:48:00.000-05:00I read about all the classes besides the PPAR/TZD,...I read about all the classes besides the PPAR/TZD, I do know the Avandia story, does it mean that the classes are dead. <BR/><BR/>I do see two drugs, one in PhaseIII, by Rheoscience (Balaglitazone) another in PhaseII by Daiichi Sankyo (Rivoglitazone. What would be the future of these classes?Anonymousnoreply@blogger.com